Study Critical Of Chinese Biotech Medicine Not Subject To Trials (China)
This article was originally published in PharmAsia News
A study of a sector of medical biotechnology practiced in China is critical of some of the drugs, stem cell and other genetic therapy being produced and performed without regulatory oversight. One of the authors said the approach being used by Beike Biotechnologies and other firms in China would mark them as "rogue companies" in the Western world. The study published in Nature Biotechnology said treatments are attracting foreigners desperate for cures even though no clinical trials have authenticated their efficacy because the State Food and Drug Administration does not require them. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.